FIELD: pharmacology.
SUBSTANCE: invention relates to N-(4-chloro-3-methyl-1.2-oxazol-5-yl)-2-[2-(6-methyl-1.3-dihydro-2-benzofuran-5-yl)acetyl]thiophene-3-sulfonamide or a pharmacologically acceptable salt thereof. The compound of the invention is intended as an endothelin receptor antagonist or therapeutic or prophylactic agent for the treatment of pulmonary arterial hypertension.
EFFECT: compound that maintains the main therapeutic effect of sitaxentan and has an improved CYP inhibitory effect.
3 cl, 4 tbl, 3 dwg, 3 ex
